ALZN
Alzamend Neuro, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Alzamend Neuro, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
—
No changes.
No changes.
No thesis.
Annual filing, covered
10-K parsed · Jul 22 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Jul 22 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
—
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Alzamend Neuro, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Alzamend Neuro, Inc..
+114.24%
shares held · 8 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Kingsbury Capital Investment | $1.6M | 48.87% | +134.52% |
| KMT Wealth | $1.6M | 48.87% | new |
| Geodeindex-like | $31,644 | 0.97% | −42.27% |
| Vanguard Fiduciary Trustindex-like | $25,224 | 0.77% | 0.00% |
| Vanguardindex-like | $9,067 | 0.28% | +71.73% |
| Manager | Value | % base | |
|---|---|---|---|
| Kingsbury Capital Investment | $1.6M | 48.87% | +134.52% |
| KMT Wealth | $1.6M | 48.87% | new |
| Geodeindex-like | $31,644 | 0.97% | −42.27% |
| Vanguard Fiduciary Trustindex-like | $25,224 | 0.77% | 0.00% |
| Vanguardindex-like | $9,067 | 0.28% | +71.73% |
Alzamend Neuro, Inc.
1.60
+0.07 · +4.58%
Expected move
No implied move.